|
시장보고서
상품코드
1473829
PEG화 단백질 시장PEGylated Proteins Market |
||||||
세계의 PEG화 단백질 시장 규모는 2023년 102억 달러에서 예측 기간 중 9.4%의 CAGR로 추이하며, 2028년말에는 159억 달러 규모로 성장할 것으로 예측됩니다.
지역별로는 북미 시장은 2023년 37억 달러에서 같은 기간 중 8.9%의 CAGR로 추이하며, 2028년말에는 56억 달러에 달할 것으로 예측되고 있습니다. 유럽 시장은 2023년 32억 달러에서 CAGR 9.5%로 추이하며, 2028년말에는 51억 달러에 달할 것으로 예측되고 있습니다.
세계의 PEG화 단백질 시장을 조사했으며, 시장 개요, 법규제 환경, 시장 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 주요 요약
- 시장의 전망
- 조사 범위
- 시장 요약
제2장 시장 개요
- PEG화 단백질의 이점
- PEG화 치료제의 한계
제3장 시장 역학
- 시장 역학 : 스냅숏
- 시장 촉진요인
- 혈액 및 종양에서의 단백질 의약품
- Biobetters의 디자인
- 시장 억제요인
- 면역원성과 부작용
- 처방의 과제
- 시장 기회
- 부위 특이적 PEG화
- 새로운 적응증과 제제 기술
제4장 신규 기술과 개발
- 비공유결합성 PEG화
- 나노입자의 PEG화
- 항체약물접합체(ADC)
제5장 시장 분석 : 각종 부문별
- 분류 내역
- 세계의 PEG화 단백질 시장 : 단백질 유형별
- 과립구집락자극인자(G-CSF)
- PEG화 모노클로널 항체
- 페그화 인터페론
- PEG화 재조합 인자
- 기타
- 세계의 PEG화 단백질 시장 : PEG화 유형별
- 직쇄 PEG화 단백질
- 분지 PEG화 단백질
- 세계의 PEG화 단백질 시장 : PEG화 용도별
- 자가면역질환
- 혈액
- 암
- 기타
- 세계의 PEG화 단백질 시장 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제6장 경쟁 정보
- 최근 동향
- 임상시험 활동
제7장 PEG화 단백질 시장에서의 지속가능성 : ESG 관점
- PEG화 단백질 산업에서의 지속가능성
- ESG 데이터 이해
- 환경 퍼포먼스
- 사회적 퍼포먼스
- 거버넌스 퍼포먼스
- BCC에 의한 결론
제8장 부록
- 조사 방법
- 전시
- 약어
- 기업 개요
- AMGEN INC.
- F. HOFFMANN-LA ROCHE LTD.
- MERCK KGAA
- PFIZER INC.
- SANDOZ GROUP AG
The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.
North American market for PEGylated proteins is expected to grow from $3.7 billion in 2023 and projected to reach $5.6 billion by the end of 2028, at a CAGR of 8.9% during the forecast period of 2023 to 2028.
The European market for PEGylated proteins is expected to grow from $3.2 billion in 2023 and projected to reach $5.1 billion by the end of 2028, at a CAGR of 9.5% during the forecast period of 2023 to 2028.
Report Scope
This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines.
In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World. For market estimates, data is provided for 2020 and 2021 (which serve as the historic years), for 2022 (the base year), and forecast for 2028.
Report Includes
- 41 data tables and 22 additional tables
- Analysis of the PEGylated proteins market
- Analyses of global market trends, with revenue data for 2021-2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2028
- Estimates of the current market size and revenue growth prospects, along with a market share analysis by product and services, protein type, application, and region
- Facts and figures pertaining to the market drivers, opportunities and restraints, and the impact of macroeconomic variables
- An analysis of recent patent grants and published patents
- A look at emerging technologies and regulatory issues
- Overview of sustainability trends and ESG developments, including consumer attitudes, companies' ESG score rankings and their ESG practices
- Insight into the competitive landscape, including companies' market shares, business segments, financials and product portfolios, as well as recent M&A activity and venture funding outlook
- Profiles of the major market players
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Introduction
- Advantages of Protein PEGylation
- Limitations of PEGylated Therapeutics
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Protein Drugs in Hematology and Oncology
- Design of Biobetters
- Market Restraints
- Immunogenicity and Side Effects
- Formulation Challenges
- Market Opportunities
- Site-Specific PEGylation
- New Indications and Formulation Techniques
Chapter 4 Emerging Technologies and Developments
- Introduction
- Non-Covalent PEGylation
- PEGylation of Nanoparticles
- Antibody-Drug Conjugates (ADCs)
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Global PEGylated Proteins Market, by Protein Type
- Granulocyte-Colony Stimulating Factors (G-CSF)
- PEGylated Monoclonal Antibodies
- PEGylated Interferons
- PEGylated Recombinant Factors
- Other Protein Types
- Global PEGylated Proteins Market, by PEGylation Type
- Linear PEGylated Proteins
- Branched PEGylated Proteins
- Global PEGylated Proteins Market, by PEGylation Application
- Autoimmune Diseases
- Hematology
- Cancer
- Other Applications
- Geographic Breakdown
- Global Market for PEGylated Proteins, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Recent Developments in the PEGylated Proteins Market
- Clinical Trial Activities
Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective
- Introduction
- Sustainability in the PEGylated Proteins Industry
- Understanding the ESG Data
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks from BCC
Chapter 8 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- AMGEN INC.
- F. HOFFMANN-LA ROCHE LTD.
- MERCK KGAA
- PFIZER INC.
- SANDOZ GROUP AG
